| 1 | end | 29,150 |
| 2 | ashi | 51 |
| 3 | back-shu | 49 |
| 4 | all-time | 18 |
| 5 | vantage | 18 |
| 6 | jing-well | 17 |
| 7 | blinded-end | 12 |
| 8 | xiaojie | 12 |
| 9 | 'end | 9 |
| 10 | non-meridian | 7 |
| 11 | baseline-to-end | 6 |
| 12 | liáng | 6 |
| 13 | supranasal | 6 |
| 14 | electro-oxidation | 4 |
| 15 | rpe/choroid | 4 |
| 16 | tianying | 4 |
| 17 | counter-ashi | 3 |
| 18 | eight-neck-occiput | 3 |
| 19 | hour-prescriptive | 3 |
| 20 | outcomes.none | 3 |
| 21 | qineihuan | 3 |
| 22 | sihua | 3 |
| 23 | activization | 2 |
| 24 | anterior-basal | 2 |
| 25 | baseline-end | 2 |
| 26 | baseline/end | 2 |
| 27 | cervical-palatal | 2 |
| 28 | esthetical | 2 |
| 29 | jing-jiaji | 2 |
| 30 | jumei | 2 |
| 31 | kuihua | 2 |
| 32 | luo-connecting | 2 |
| 33 | post-therapy/test | 2 |
| 34 | si-6 | 2 |
| 35 | sisto | 2 |
| 36 | 'tipping | 1 |
| 37 | -11.1±13.3 | 1 |
| 38 | -20·8 | 1 |
| 39 | -25·1 | 1 |
| 40 | -9.42,100 | 1 |
| 41 | 0.85+/-0.06 | 1 |
| 42 | 0.9+/-1.8 | 1 |
| 43 | 0.9-1.43 | 1 |
| 44 | 0.9±1.6 | 1 |
| 45 | 1.0+/-1.9 | 1 |
| 46 | 1.2+/-2.1 | 1 |
| 47 | 1.4+/-2.1 | 1 |
| 48 | 12h-time | 1 |
| 49 | 13.9±2.7 | 1 |
| 50 | 17.1±3.0 | 1 |
| 51 | 1=six | 1 |
| 52 | 2.0±0,9 | 1 |
| 53 | 2.44-3.30 | 1 |
| 54 | 2.44-3.42 | 1 |
| 55 | 2.7+/-2.5 | 1 |
| 56 | 2.75±1.86 | 1 |
| 57 | 2.8+/-2.6 | 1 |
| 58 | 3,7+/-2,2 | 1 |
| 59 | 3.8+/-4.1 | 1 |
| 60 | 3.9+/-2.6 | 1 |
| 61 | 34-67 | 1 |
| 62 | 36.5+/-7.7 | 1 |
| 63 | 4.3+/-6.2 | 1 |
| 64 | 4.5-percentage | 1 |
| 65 | 4.5/4 | 1 |
| 66 | 4.7±0,6 | 1 |
| 67 | 4.7±2.5 | 1 |
| 68 | 5.2+/-2.5 | 1 |
| 69 | 5.2+/-5.5 | 1 |
| 70 | 6.0+/-3.0 | 1 |
| 71 | 6.1+/-2.8 | 1 |
| 72 | 6.51-9.45 | 1 |
| 73 | 6.72-9.82 | 1 |
| 74 | 7-time | 1 |
| 75 | 7.1+/-2.9 | 1 |
| 76 | 7.5-8.4 | 1 |
| 77 | 8.1-24.5 | 1 |
| 78 | 8.4±0.2 | 1 |
| 79 | 84.3±10.2 | 1 |
| 80 | acetabulum:4 | 1 |
| 81 | andtolerability | 1 |
| 82 | ankle:1 | 1 |
| 83 | appl1-positive | 1 |
| 84 | blinded-to-end | 1 |
| 85 | calf:3 | 1 |
| 86 | catheter-ablation | 1 |
| 87 | cee/progestogen | 1 |
| 88 | chlorhexidine/gutta-percha | 1 |
| 89 | cuase | 1 |
| 90 | days:1 | 1 |
| 91 | days:2 | 1 |
| 92 | disambiguation | 1 |
| 93 | each-measurement | 1 |
| 94 | edp/end | 1 |
| 95 | eminence-based | 1 |
| 96 | endpoint-risk | 1 |
| 97 | evideence | 1 |
| 98 | femur:7 | 1 |
| 99 | four-flower | 1 |
| 100 | four-gate | 1 |
| 101 | hypomuscularity | 1 |
| 102 | isoconductivity | 1 |
| 103 | isodichroic | 1 |
| 104 | isoeletronic | 1 |
| 105 | krafft | 1 |
| 106 | maximum-count | 1 |
| 107 | nasion-a | 1 |
| 108 | no:1 | 1 |
| 109 | non-decision | 1 |
| 110 | non-trigger | 1 |
| 111 | onco-gynecological | 1 |
| 112 | onset/progression/peak | 1 |
| 113 | optimal-cutoff | 1 |
| 114 | outcome-completion | 1 |
| 115 | outcome-diagnosis | 1 |
| 116 | outcomes-sum | 1 |
| 117 | outcomes.relief | 1 |
| 118 | pprt2 | 1 |
| 119 | preparenthood | 1 |
| 120 | prevention.programming | 1 |
| 121 | pwdti-measured | 1 |
| 122 | sella-nasion-a | 1 |
| 123 | sella-nasion-b | 1 |
| 124 | source-field | 1 |
| 125 | st-j | 1 |
| 126 | t46i | 1 |
| 127 | three-back | 1 |
| 128 | three-nose | 1 |
| 129 | use-of-the-system | 1 |
| 130 | volume-normalized | 1 |
| 131 | yes:2 | 1 |
| 132 | zero-velocity | 1 |
| 133 | δ=5 | 1 |
| 134 | ⩾9 | 1 |
| 1 | 'end | 9 |
| 2 | 'tipping | 1 |
| 3 | -11.1±13.3 | 1 |
| 4 | -20·8 | 1 |
| 5 | -25·1 | 1 |
| 6 | -9.42,100 | 1 |
| 7 | 0.85+/-0.06 | 1 |
| 8 | 0.9+/-1.8 | 1 |
| 9 | 0.9-1.43 | 1 |
| 10 | 0.9±1.6 | 1 |
| 11 | 1.0+/-1.9 | 1 |
| 12 | 1.2+/-2.1 | 1 |
| 13 | 1.4+/-2.1 | 1 |
| 14 | 12h-time | 1 |
| 15 | 13.9±2.7 | 1 |
| 16 | 17.1±3.0 | 1 |
| 17 | 1=six | 1 |
| 18 | 2.0±0,9 | 1 |
| 19 | 2.44-3.30 | 1 |
| 20 | 2.44-3.42 | 1 |
| 21 | 2.7+/-2.5 | 1 |
| 22 | 2.75±1.86 | 1 |
| 23 | 2.8+/-2.6 | 1 |
| 24 | 3,7+/-2,2 | 1 |
| 25 | 3.8+/-4.1 | 1 |
| 26 | 3.9+/-2.6 | 1 |
| 27 | 34-67 | 1 |
| 28 | 36.5+/-7.7 | 1 |
| 29 | 4.3+/-6.2 | 1 |
| 30 | 4.5-percentage | 1 |
| 31 | 4.5/4 | 1 |
| 32 | 4.7±0,6 | 1 |
| 33 | 4.7±2.5 | 1 |
| 34 | 5.2+/-2.5 | 1 |
| 35 | 5.2+/-5.5 | 1 |
| 36 | 6.0+/-3.0 | 1 |
| 37 | 6.1+/-2.8 | 1 |
| 38 | 6.51-9.45 | 1 |
| 39 | 6.72-9.82 | 1 |
| 40 | 7-time | 1 |
| 41 | 7.1+/-2.9 | 1 |
| 42 | 7.5-8.4 | 1 |
| 43 | 8.1-24.5 | 1 |
| 44 | 8.4±0.2 | 1 |
| 45 | 84.3±10.2 | 1 |
| 46 | acetabulum:4 | 1 |
| 47 | activization | 2 |
| 48 | all-time | 18 |
| 49 | andtolerability | 1 |
| 50 | ankle:1 | 1 |
| 51 | anterior-basal | 2 |
| 52 | appl1-positive | 1 |
| 53 | ashi | 51 |
| 54 | back-shu | 49 |
| 55 | baseline-end | 2 |
| 56 | baseline-to-end | 6 |
| 57 | baseline/end | 2 |
| 58 | blinded-end | 12 |
| 59 | blinded-to-end | 1 |
| 60 | calf:3 | 1 |
| 61 | catheter-ablation | 1 |
| 62 | cee/progestogen | 1 |
| 63 | cervical-palatal | 2 |
| 64 | chlorhexidine/gutta-percha | 1 |
| 65 | counter-ashi | 3 |
| 66 | cuase | 1 |
| 67 | days:1 | 1 |
| 68 | days:2 | 1 |
| 69 | disambiguation | 1 |
| 70 | each-measurement | 1 |
| 71 | edp/end | 1 |
| 72 | eight-neck-occiput | 3 |
| 73 | electro-oxidation | 4 |
| 74 | eminence-based | 1 |
| 75 | end | 29,150 |
| 76 | endpoint-risk | 1 |
| 77 | esthetical | 2 |
| 78 | evideence | 1 |
| 79 | femur:7 | 1 |
| 80 | four-flower | 1 |
| 81 | four-gate | 1 |
| 82 | hour-prescriptive | 3 |
| 83 | hypomuscularity | 1 |
| 84 | isoconductivity | 1 |
| 85 | isodichroic | 1 |
| 86 | isoeletronic | 1 |
| 87 | jing-jiaji | 2 |
| 88 | jing-well | 17 |
| 89 | jumei | 2 |
| 90 | krafft | 1 |
| 91 | kuihua | 2 |
| 92 | liáng | 6 |
| 93 | luo-connecting | 2 |
| 94 | maximum-count | 1 |
| 95 | nasion-a | 1 |
| 96 | no:1 | 1 |
| 97 | non-decision | 1 |
| 98 | non-meridian | 7 |
| 99 | non-trigger | 1 |
| 100 | onco-gynecological | 1 |
| 101 | onset/progression/peak | 1 |
| 102 | optimal-cutoff | 1 |
| 103 | outcome-completion | 1 |
| 104 | outcome-diagnosis | 1 |
| 105 | outcomes-sum | 1 |
| 106 | outcomes.none | 3 |
| 107 | outcomes.relief | 1 |
| 108 | post-therapy/test | 2 |
| 109 | pprt2 | 1 |
| 110 | preparenthood | 1 |
| 111 | prevention.programming | 1 |
| 112 | pwdti-measured | 1 |
| 113 | qineihuan | 3 |
| 114 | rpe/choroid | 4 |
| 115 | sella-nasion-a | 1 |
| 116 | sella-nasion-b | 1 |
| 117 | si-6 | 2 |
| 118 | sihua | 3 |
| 119 | sisto | 2 |
| 120 | source-field | 1 |
| 121 | st-j | 1 |
| 122 | supranasal | 6 |
| 123 | t46i | 1 |
| 124 | three-back | 1 |
| 125 | three-nose | 1 |
| 126 | tianying | 4 |
| 127 | use-of-the-system | 1 |
| 128 | vantage | 18 |
| 129 | volume-normalized | 1 |
| 130 | xiaojie | 12 |
| 131 | yes:2 | 1 |
| 132 | zero-velocity | 1 |
| 133 | δ=5 | 1 |
| 134 | ⩾9 | 1 |
| 1 | 6.0+/-3.0 | 1 |
| 2 | 17.1±3.0 | 1 |
| 3 | -9.42,100 | 1 |
| 4 | 2.44-3.30 | 1 |
| 5 | 1.2+/-2.1 | 1 |
| 6 | 1.4+/-2.1 | 1 |
| 7 | 3.8+/-4.1 | 1 |
| 8 | ankle:1 | 1 |
| 9 | no:1 | 1 |
| 10 | days:1 | 1 |
| 11 | -25·1 | 1 |
| 12 | 3,7+/-2,2 | 1 |
| 13 | 84.3±10.2 | 1 |
| 14 | 8.4±0.2 | 1 |
| 15 | 4.3+/-6.2 | 1 |
| 16 | 2.44-3.42 | 1 |
| 17 | 6.72-9.82 | 1 |
| 18 | yes:2 | 1 |
| 19 | days:2 | 1 |
| 20 | pprt2 | 1 |
| 21 | -11.1±13.3 | 1 |
| 22 | 0.9-1.43 | 1 |
| 23 | calf:3 | 1 |
| 24 | 7.5-8.4 | 1 |
| 25 | 4.5/4 | 1 |
| 26 | acetabulum:4 | 1 |
| 27 | 5.2+/-2.5 | 1 |
| 28 | 2.7+/-2.5 | 1 |
| 29 | 4.7±2.5 | 1 |
| 30 | 8.1-24.5 | 1 |
| 31 | 5.2+/-5.5 | 1 |
| 32 | 6.51-9.45 | 1 |
| 33 | δ=5 | 1 |
| 34 | 4.7±0,6 | 1 |
| 35 | si-6 | 2 |
| 36 | 0.9±1.6 | 1 |
| 37 | 2.8+/-2.6 | 1 |
| 38 | 3.9+/-2.6 | 1 |
| 39 | 0.85+/-0.06 | 1 |
| 40 | 2.75±1.86 | 1 |
| 41 | 13.9±2.7 | 1 |
| 42 | 36.5+/-7.7 | 1 |
| 43 | 34-67 | 1 |
| 44 | femur:7 | 1 |
| 45 | 0.9+/-1.8 | 1 |
| 46 | 6.1+/-2.8 | 1 |
| 47 | -20·8 | 1 |
| 48 | 2.0±0,9 | 1 |
| 49 | 1.0+/-1.9 | 1 |
| 50 | 7.1+/-2.9 | 1 |
| 51 | ⩾9 | 1 |
| 52 | nasion-a | 1 |
| 53 | sella-nasion-a | 1 |
| 54 | chlorhexidine/gutta-percha | 1 |
| 55 | sihua | 3 |
| 56 | kuihua | 2 |
| 57 | sella-nasion-b | 1 |
| 58 | isoeletronic | 1 |
| 59 | isodichroic | 1 |
| 60 | pwdti-measured | 1 |
| 61 | eminence-based | 1 |
| 62 | volume-normalized | 1 |
| 63 | rpe/choroid | 4 |
| 64 | source-field | 1 |
| 65 | end | 29,150 |
| 66 | 'end | 9 |
| 67 | blinded-end | 12 |
| 68 | baseline-end | 2 |
| 69 | blinded-to-end | 1 |
| 70 | baseline-to-end | 6 |
| 71 | baseline/end | 2 |
| 72 | edp/end | 1 |
| 73 | preparenthood | 1 |
| 74 | evideence | 1 |
| 75 | vantage | 18 |
| 76 | 4.5-percentage | 1 |
| 77 | xiaojie | 12 |
| 78 | 7-time | 1 |
| 79 | 12h-time | 1 |
| 80 | all-time | 18 |
| 81 | outcomes.none | 3 |
| 82 | cuase | 1 |
| 83 | three-nose | 1 |
| 84 | four-gate | 1 |
| 85 | appl1-positive | 1 |
| 86 | hour-prescriptive | 3 |
| 87 | outcomes.relief | 1 |
| 88 | optimal-cutoff | 1 |
| 89 | prevention.programming | 1 |
| 90 | 'tipping | 1 |
| 91 | luo-connecting | 2 |
| 92 | tianying | 4 |
| 93 | liáng | 6 |
| 94 | t46i | 1 |
| 95 | jumei | 2 |
| 96 | ashi | 51 |
| 97 | counter-ashi | 3 |
| 98 | jing-jiaji | 2 |
| 99 | st-j | 1 |
| 100 | onset/progression/peak | 1 |
| 101 | three-back | 1 |
| 102 | endpoint-risk | 1 |
| 103 | onco-gynecological | 1 |
| 104 | esthetical | 2 |
| 105 | anterior-basal | 2 |
| 106 | supranasal | 6 |
| 107 | cervical-palatal | 2 |
| 108 | jing-well | 17 |
| 109 | use-of-the-system | 1 |
| 110 | outcomes-sum | 1 |
| 111 | non-meridian | 7 |
| 112 | qineihuan | 3 |
| 113 | cee/progestogen | 1 |
| 114 | non-decision | 1 |
| 115 | electro-oxidation | 4 |
| 116 | catheter-ablation | 1 |
| 117 | disambiguation | 1 |
| 118 | activization | 2 |
| 119 | outcome-completion | 1 |
| 120 | sisto | 2 |
| 121 | non-trigger | 1 |
| 122 | four-flower | 1 |
| 123 | outcome-diagnosis | 1 |
| 124 | krafft | 1 |
| 125 | each-measurement | 1 |
| 126 | maximum-count | 1 |
| 127 | post-therapy/test | 2 |
| 128 | eight-neck-occiput | 3 |
| 129 | back-shu | 49 |
| 130 | 1=six | 1 |
| 131 | zero-velocity | 1 |
| 132 | andtolerability | 1 |
| 133 | hypomuscularity | 1 |
| 134 | isoconductivity | 1 |